1. Market Research
  2. > Business Services
  3. > Research and Development Market Trends
  4. > PharmaIN Corporation - Product Pipeline Review - 2014

PharmaIN Corporation - Product Pipeline Review - 2014

  • December 2014
  • -
  • Global Markets Direct
  • -
  • 31 pages

PharmaIN Corporation - Product Pipeline Review - 2014

Summary

Global Markets Direct’s, ‘PharmaIN Corporation - Product Pipeline Review - 2014’, provides an overview of the PharmaIN Corporation’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of PharmaIN Corporation’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of PharmaIN Corporation including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of PharmaIN Corporation’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the PharmaIN Corporation’s pipeline products

Reasons to buy

- Evaluate PharmaIN Corporation’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of PharmaIN Corporation in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the PharmaIN Corporation’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of PharmaIN Corporation and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of PharmaIN Corporation
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of PharmaIN Corporation and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

PharmaIN Corporation - Product Pipeline Review - 2014
Table of Contents
PharmaIN Corporation Snapshot 5
PharmaIN Corporation Overview 5
Key Information 5
Key Facts 5
PharmaIN Corporation - Research and Development Overview 6
Key Therapeutic Areas 6
PharmaIN Corporation - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Out-Licensed Products 11
Out-Licensed Products/Combination Treatment Modalities 12
PharmaIN Corporation - Pipeline Products Glance 13
PharmaIN Corporation - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Discovery Products/Combination Treatment Modalities 14
PharmaIN Corporation - Drug Profiles 15
PGC Anti-MRSA 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
PGC Basal Insulin 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
PGC Based hbEGF 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
PGC Based Natriuretic Peptides 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
PGC GLP-1 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
PGC-VIP 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
PHIN-837 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
Drugs for Inflammation 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
PGC EGF-Gastrin 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
Undisclosed Peptide For Liver Cirrhosis 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
PharmaIN Corporation - Pipeline Analysis 25
PharmaIN Corporation - Pipeline Products by Target 25
PharmaIN Corporation - Pipeline Products by Route of Administration 26
PharmaIN Corporation - Pipeline Products by Molecule Type 27
PharmaIN Corporation - Pipeline Products by Mechanism of Action 28
PharmaIN Corporation - Locations And Subsidiaries 29
Head Office 29
Appendix 30
Methodology 30
Coverage 30
Secondary Research 30
Primary Research 30
Expert Panel Validation 30
Contact Us 31
Disclaimer 31

List of Tables

PharmaIN Corporation, Key Information 5
PharmaIN Corporation, Key Facts 5
PharmaIN Corporation - Pipeline by Indication, 2014 8
PharmaIN Corporation - Pipeline by Stage of Development, 2014 9
PharmaIN Corporation - Monotherapy Products in Pipeline, 2014 10
PharmaIN Corporation - Out-Licensed Products in Pipeline, 2014 11
PharmaIN Corporation - Out-Licensed Products/ Combination Treatment Modalities, 2014 12
PharmaIN Corporation - Preclinical, 2014 13
PharmaIN Corporation - Discovery, 2014 14
PharmaIN Corporation - Pipeline by Target, 2014 25
PharmaIN Corporation - Pipeline by Route of Administration, 2014 26
PharmaIN Corporation - Pipeline by Molecule Type, 2014 27
PharmaIN Corporation - Pipeline Products by Mechanism of Action, 2014 28

List of Figures

PharmaIN Corporation - Pipeline by Top 10 Indication, 2014 7
PharmaIN Corporation - Pipeline by Stage of Development, 2014 9
PharmaIN Corporation - Monotherapy Products in Pipeline, 2014 10
PharmaIN Corporation - Pipeline by Top 10 Target, 2014 25
PharmaIN Corporation - Pipeline by Top 10 Route of Administration, 2014 26
PharmaIN Corporation - Pipeline by Top 10 Molecule Type, 2014 27
PharmaIN Corporation - Pipeline Products by Top 10 Mechanism of Action, 2014 28

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016

Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016’, provides in depth analysis on Integrin Alpha 7 (ITGA7) ...

Pulmonary Fibrosis - Pipeline Review, H2 2016

Pulmonary Fibrosis - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Pulmonary Fibrosis - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Pulmonary Fibrosis - Pipeline Review, H2 2016’, provides an overview of the Pulmonary Fibrosis pipeline landscape. ...

Cognitive Impairment - Pipeline Review, H2 2016

Cognitive Impairment - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Cognitive Impairment - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Cognitive Impairment - Pipeline Review, H2 2016’, provides an overview of the Cognitive Impairment pipeline landscape. ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.